• Explore /
  • Poster
  • / Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

Abstract Poster

Authors

Eric Winer

Eric P. Winer

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Eric P. Winer , Oleg Lipatov , Seock-Ah Im , Anthony Goncalves , Eva Muñoz-Couselo , Keun Seok Lee , Peter Schmid , Laura Testa , Isabell Witzel , Shoichiro Ohtani , Jared Lunceford , Vassiliki Karantza , Jaime Alberto Mejia , Razvan Cristescu , Deepti Aurora-Garg , Petar Jelinic , Lingkang Huang , Javier Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02555657

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1013)

DOI

10.1200/JCO.2020.38.15_suppl.1013

Abstract #

1013

Poster Bd #

98

Abstract Disclosures

Similar Posters

First Author: Eric P. Winer

First Author: Joyce O'Shaughnessy

First Author: Johannes Ettl

First Author: David Graham